AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine (Adjuvanted RSVPreF3): Review of the First 2 Years of Post-Marketing Safety Surveillance.
Saved in:
| Title: | AS01 |
|---|---|
| Authors: | Tregunno C; GSK, London, UK., Deraedt Q; GSK, Av. Fleming 20, 1300, Wavre, Belgium. quentin.x.deraedt@gsk.com., Cuadripani S; GSK, Stevenage, UK., Verheust C; GSK, Av. Fleming 20, 1300, Wavre, Belgium., Bryan P; GSK, London, UK. |
| Source: | Drug safety [Drug Saf] 2026 Aug 01. Date of Electronic Publication: 2026 Aug 01. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 9002928 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1942 (Electronic) Linking ISSN: 01145916 NLM ISO Abbreviation: Drug Saf Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1179-1942 |
|---|---|
| DOI: | 10.1007/s40264-026-01698-y |
